ABVD vs. radiotherapy in early stage Hodgkin's lymphoma A critical look at the NCIC HD.6 trial

被引：0
|
作者：
Wenz, F. [1 ]
Abo-Madyan, Y. [1 ]
Welzel, G. [1 ]
Giordano, F. A. [1 ]
机构：
[1] Heidelberg Univ, Univ Med Ctr Mannheim, D-68167 Mannheim, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2012年 / 188卷 / 08期
关键词：
2ND MALIGNANCIES; DISEASE; CANCER; RADIATION; CHEMOTHERAPY; THERAPY; INTENSITY; NEOPLASMS; LEUKEMIA; COHORT;
D O I：
10.1007/s00066-012-0151-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：649 / 652
页数：4
相关论文
共 50 条
  • [21] Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations
    Christian Fiandra
    Andrea Riccardo Filippi
    Paola Catuzzo
    Angela Botticella
    Patrizia Ciammella
    Pierfrancesco Franco
    Valeria Casanova Borca
    Riccardo Ragona
    Santi Tofani
    Umberto Ricardi
    Radiation Oncology, 7
  • [22] Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy
    Gobbi, Paolo G.
    Bassi, Emilio
    Bergonzi, Manuela
    Merli, Francesco
    Coriani, Chiara
    Iannitto, Emilio
    Luminari, Stefano
    Polimeno, Giuseppe
    Federico, Massimo
    HEMATOLOGICAL ONCOLOGY, 2012, 30 (04) : 194 - 199
  • [23] IMPACT OF BLEOMYCIN AND DACARBAZINE WITHIN THE ABVD REGIMEN IN THE TREATMENT OF EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE GHSG HD13 TRIAL
    Behringer, K.
    Goergen, H.
    Borchmann, P.
    Diehl, V.
    Fuchs, M.
    Lohri, A.
    Hitz, F.
    Zijlstra, J. M.
    Greil, R.
    Markova, J.
    Topp, M. S.
    Soekler, M.
    Mathas, S.
    Meissner, J.
    von Tresckow, B.
    Boell, B.
    Engert, A.
    HAEMATOLOGICA, 2014, 99 : 497 - 497
  • [24] Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles ABVD in early stage Hodgkin's disease:: interim results of the German Hodgkin's Lymphoma Study Group (GHSG) trial hd10
    Müller, RP
    Eich, HT
    Wolf, J
    Pfistner, B
    Engert, A
    Diehl, V
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S205 - S205
  • [25] Involved-node radiotherapy in early-stage Hodgkin's lymphoma
    Eich, H. T.
    Zimmermann, C.
    Mueller, R.-P.
    ONKOLOGE, 2010, 16 (01): : 35 - +
  • [26] Radiotherapy in early stage Hodgkin's lymphoma: The importance of volume and treatment position
    Reymen, Bart
    Spiessens, Sylvie
    Lievens, Yolande
    RADIOTHERAPY AND ONCOLOGY, 2010, 95 (02) : 225 - 228
  • [27] Involved-node radiotherapy in early-stage Hodgkin's lymphoma
    Eich, Hans Theodor
    Mueller, Rolf-Peter
    Engenhart-Cabillic, Rita
    Lukas, Peter
    Schmidberger, Heinz
    Staar, Susanne
    Willich, Normann
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 (08) : 406 - 410
  • [28] Comparison of ABVD chemotherapy and a regimen including radiotherapy in patients with limited-stage Non-Hodgkin’s lymphoma
    Carol S. Portlock
    Current Oncology Reports, 2006, 8 (5) : 355 - 356
  • [29] Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: Final results of the German Hodgkin's Lymphoma Study Group trial HD5
    Sieber, M
    Tesch, H
    Pfistner, B
    Rueffer, U
    Lathan, B
    Brosteanu, O
    Paulus, U
    Koch, T
    Pfreundschuh, M
    Loeffler, M
    Engert, A
    Josting, A
    Wolf, J
    Hasenclever, D
    Franklin, J
    Duehmke, E
    Georgii, A
    Schalk, KP
    Kirchner, H
    Doelken, G
    Munker, R
    Koch, P
    Herrmann, R
    Greil, R
    Anselmo, AP
    Diehl, V
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 476 - 484
  • [30] Involved field(IF) vs. extended field (EF) radiotherapy (RT) for patients in early unfavorable stages of Hodgkin's lymphoma (HL): 10-year update of the HD8 trial of the German Hodgkin Study Group (GHSG)
    Kriz, J.
    Sasse, S.
    Klimm, B.
    Goergen, H.
    Mueller, R. -P
    Diehl, V
    Borchmann, P.
    Engert, A.
    Eich, H. -T
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 30 - 30
12345